Wilton John sold $73K of AUNA

Wilton John sold 17,574 shares of AUNA S.A. (AUNA) at $4.17 on 2026-05-28.

Original reporting
SEC EDGAR · Wilton John
Published Jun 2, 2026, 12:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 1:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AUNA
Neutral
medium confidence
Mentioned
$AUNA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AUNANeutralLow
01

Why it matters

Traders may briefly reassess sentiment around AUNA due to insider selling, but there is no new corporate event (earnings, guidance, contract, litigation) to reprice fundamentals.

02

Market read

AUNA receives a new, timestamped insider-selling datapoint at a specific price, which can influence short-term sentiment but not fundamentals by itself.

03

What to watch

Insider sales often cluster around personal tax/liquidity needs; without follow-on buys or broader insider trend, price impact may be limited.

Relevance 6/10Novelty 6/10Timing: Filed after-hours/next session visibility (SEC Form 4 filed 2026-06-01T20:46:04-04:00; sale dated 2026-05-28).

Background

The article is an SEC EDGAR Form 4 disclosure of an insider (director) open-market sale of AUNA shares.

Company-level read

Ticker impact

$AUNANeutralMedium confidence
Context

SEC Form 4 shows director Wilton John sold 17,574 AUNA shares in an open-market transaction at $4.1711/share.

Expected impact

Likely modest/short-lived negative bias if traders interpret as reduced confidence; no clear catalyst for a sustained move.

Evidence & confidence

The filing is a disclosed insider transaction with no accompanying company-specific operational or financial news; size is relatively small and lacks 10b5-1 context.

Market effects

Minimal—this is company-specific insider activity, not a sector-wide regulatory or competitive development.

Minimal; no regional macro or cross-border transaction details provided.

Low; no global deal, litigation, or guidance change mentioned.

Counterpoint

The sale may be routine liquidity/portfolio rebalancing; absence of a 10b5-1 plan does not automatically imply bearish fundamentals.

Key entities

  • AUNA S.A.

    Subject of the Form 4 insider transaction; director Wilton John sold shares.

  • Wilton John

    Director who executed the open-market sale of 17,574 shares on 2026-05-28.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AUNAMed

Auna S.A. (AUNA) Stock Falls on Q3 2026 Earnings

Auna S.A. (AUNA) reported Q3 2026 revenue of $384.7M, up 19.4% YoY, with net income falling 57.4% to $5.9M. Operating cash flow rose 38.9% to $77.6M. Insiders made 6 purchases and 1 sale in the past 6 months. Hedge funds showed mixed activity, with some increasing and others decreasing positions.

$AUNAMed

AUNA S.A. (AUNA): Financial results for Q3 2026

AUNA S.A. (AUNA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Auna Announces 3Q26 Financial Results Auna reports 10% FX-Neutral Revenue Growth and Continued Strong Cash Generation in 3Q2026; Mexico Returns to Year-over-Year Adjusted EBITDA Growth; Profitability Pressured by Specific Headwinds in Colombia and Peru Leverage Impro

$AUNAHigh

Why is Auna stock dropping today?

Auna SAA ADR stock fell 9.2% to $4.91 after revising its 2026 profitability outlook, citing higher cancer diagnosis costs in Colombia. The company maintained its revenue growth target but saw a sell-off amid broader market declines. The stock dropped to a session low of $4.55, nearing its 52-week low of $4.09.

$AUNAMed

Auna (AUNA) Q2 2026 Earnings Call Transcript

Auna (AUNA) reported Q2 2026 results with 9% revenue growth driven by volume and higher complexity services. Adjusted EBITDA declined 9% due to margin pressures in Mexico and Colombia, and billing penalties in Peru. Mexico saw 7% surgery and 20% oncology volume growth, while Peru achieved 8% revenue growth. Colombia's adjusted EBITDA increased 18% sequentially. Leverage decreased to 3.6x, and cash increased 43% year-over-year.